Phesgo and Tecentriq Performance and Approvals

2023 outlook Group sales growth1 Low single digit decline Core EPS growth¹ Broadly in line with sales decline Dividend outlook Further increase dividend in Swiss francs 1 At Constant Exchange Rates (CER) Roche 15

View entire presentation